FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741796350> ?p ?o ?g. }

• W2741796350 endingPage "4607" @default.
• W2741796350 startingPage "4607" @default.
• W2741796350 abstract "Abstract Purpose: Immunotherapies targeting immune checkpoint receptors have shown great promise for a subset of cancer patients; however, robust and safe combination therapies are still needed. In the tumor microenvironment, prostaglandin E2 receptor type 4 (EP4) signaling has been implicated in both protumoral myeloid cell differentiation and cytotoxic T cell exhaustion. We evaluated the combination of the EP4 antagonist E7046 (clinical trial NCT02540291) with anti-PD1 or anti-CTLA4 in preclinical tumor models, and also interrogated the relationship between PGE2 pathway activation and cancer patient survival. Materials/Methods: Mouse syngeneic tumor models CT-26 and 4T1 were used for pharmacological investigation. GMP grade E7046 was administered to tumor-bearing animals by oral gavage. Co-culture of EG7-OVA and OT1 cells in an antigen-specific cytotoxic T cell (CTL) activation assay provided mechanistic insights. For translational validation, transcripts of five major genes involved in PGE2 synthesis, transport and degradation were compared between malignant and normal tissues across all TCGA tumor types, and correlation of their expression with overall survival was assessed. Results: In the CT26 tumor model, the combination of E7046 and anti-PD1 resulted in significantly more tumor-free animals compared with either agent alone. In the 4T1 tumor model, the combination of E7046 and anti-CTLA4 was also more effective in suppressing tumor growth and tumor rejection compared with anti-CTLA4 alone, and was accompanied by a markedly increased accumulation of GZMB+CD8T+ CTLs in the treated tumors. Consistent with those findings, addition of anti-PD1 antibody promoted OVA-specific CTL activation in vitro while addition of PGE2 strongly inhibited it, as measured by IFNγ secretion. Inclusion of E7046 dose-dependently reversed the PGE2-induced suppressive activity in the presence of anti-PD1 antibody. Among major human PGE2 pathway genes, TCGA analysis showed that PTGES1 was upregulated and HPGD downregulated across a broad range of tumor types. In contrast, COX1, COX2 and PGT showed less difference between malignant and normal tissues. Importantly, these differences of one or multiple PGE2 pathway genes were strongly associated with patient survival in certain cancer types. Conclusions: A subset of human cancer types displays upregulated PGE2 pathway that is associated with a poorer prognosis. PGE2-EP4 signaling potently suppresses antigen-specific CTL activation in the presence of PD1 signaling blockade. The combination of EP4 antagonist E7046 with either anti-PD1 or anti-CTLA4 demonstrated superior anti-tumor activity compared with anti-PD1 or anti-CTLA4 alone. This increased activity was accompanied by increased CTL activation. Citation Format: Diana I. Albu, David Verbel, Yuan Huang, Donna Kolber-Simonds, Zichun Wang, Xulong Wang, Zoltan Dezso, Christy Ingersoll, Kuan-Chun Huang, Janna Hutz, Mary Woodall-Jappe, Xingfeng Bao. Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4607. doi:10.1158/1538-7445.AM2017-4607" @default.
• W2741796350 created "2017-08-08" @default.
• W2741796350 creator A5008066397 @default.
• W2741796350 creator A5008426990 @default.
• W2741796350 creator A5015024554 @default.
• W2741796350 creator A5045462016 @default.
• W2741796350 creator A5054020569 @default.
• W2741796350 creator A5057114998 @default.
• W2741796350 creator A5059298132 @default.
• W2741796350 creator A5060511746 @default.
• W2741796350 creator A5065592547 @default.
• W2741796350 creator A5070503646 @default.
• W2741796350 creator A5072794263 @default.
• W2741796350 creator A5076552144 @default.
• W2741796350 date "2017-07-01" @default.
• W2741796350 modified "2023-10-14" @default.
• W2741796350 title "Abstract 4607: Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity" @default.
• W2741796350 doi "https://doi.org/10.1158/1538-7445.am2017-4607" @default.
• W2741796350 hasPublicationYear "2017" @default.
• W2741796350 type Work @default.
• W2741796350 sameAs 2741796350 @default.
• W2741796350 citedByCount "1" @default.
• W2741796350 countsByYear W27417963502022 @default.
• W2741796350 crossrefType "journal-article" @default.
• W2741796350 hasAuthorship W2741796350A5008066397 @default.
• W2741796350 hasAuthorship W2741796350A5008426990 @default.
• W2741796350 hasAuthorship W2741796350A5015024554 @default.
• W2741796350 hasAuthorship W2741796350A5045462016 @default.
• W2741796350 hasAuthorship W2741796350A5054020569 @default.
• W2741796350 hasAuthorship W2741796350A5057114998 @default.
• W2741796350 hasAuthorship W2741796350A5059298132 @default.
• W2741796350 hasAuthorship W2741796350A5060511746 @default.
• W2741796350 hasAuthorship W2741796350A5065592547 @default.
• W2741796350 hasAuthorship W2741796350A5070503646 @default.
• W2741796350 hasAuthorship W2741796350A5072794263 @default.
• W2741796350 hasAuthorship W2741796350A5076552144 @default.
• W2741796350 hasConcept C121608353 @default.
• W2741796350 hasConcept C126322002 @default.
• W2741796350 hasConcept C147483822 @default.
• W2741796350 hasConcept C147969180 @default.
• W2741796350 hasConcept C154317977 @default.
• W2741796350 hasConcept C167672396 @default.
• W2741796350 hasConcept C202751555 @default.
• W2741796350 hasConcept C203014093 @default.
• W2741796350 hasConcept C2776090121 @default.
• W2741796350 hasConcept C2776107976 @default.
• W2741796350 hasConcept C2777701055 @default.
• W2741796350 hasConcept C2780674031 @default.
• W2741796350 hasConcept C502942594 @default.
• W2741796350 hasConcept C55493867 @default.
• W2741796350 hasConcept C71924100 @default.
• W2741796350 hasConcept C86803240 @default.
• W2741796350 hasConcept C8891405 @default.
• W2741796350 hasConceptScore W2741796350C121608353 @default.
• W2741796350 hasConceptScore W2741796350C126322002 @default.
• W2741796350 hasConceptScore W2741796350C147483822 @default.
• W2741796350 hasConceptScore W2741796350C147969180 @default.
• W2741796350 hasConceptScore W2741796350C154317977 @default.
• W2741796350 hasConceptScore W2741796350C167672396 @default.
• W2741796350 hasConceptScore W2741796350C202751555 @default.
• W2741796350 hasConceptScore W2741796350C203014093 @default.
• W2741796350 hasConceptScore W2741796350C2776090121 @default.
• W2741796350 hasConceptScore W2741796350C2776107976 @default.
• W2741796350 hasConceptScore W2741796350C2777701055 @default.
• W2741796350 hasConceptScore W2741796350C2780674031 @default.
• W2741796350 hasConceptScore W2741796350C502942594 @default.
• W2741796350 hasConceptScore W2741796350C55493867 @default.
• W2741796350 hasConceptScore W2741796350C71924100 @default.
• W2741796350 hasConceptScore W2741796350C86803240 @default.
• W2741796350 hasConceptScore W2741796350C8891405 @default.
• W2741796350 hasIssue "13_Supplement" @default.
• W2741796350 hasLocation W27417963501 @default.
• W2741796350 hasOpenAccess W2741796350 @default.
• W2741796350 hasPrimaryLocation W27417963501 @default.
• W2741796350 hasRelatedWork W1541149498 @default.
• W2741796350 hasRelatedWork W2053177727 @default.
• W2741796350 hasRelatedWork W2063827993 @default.
• W2741796350 hasRelatedWork W2090726975 @default.
• W2741796350 hasRelatedWork W2791825614 @default.
• W2741796350 hasRelatedWork W2884754721 @default.
• W2741796350 hasRelatedWork W3025154575 @default.
• W2741796350 hasRelatedWork W3039388108 @default.
• W2741796350 hasRelatedWork W3120170523 @default.
• W2741796350 hasRelatedWork W3198713608 @default.
• W2741796350 hasVolume "77" @default.
• W2741796350 isParatext "false" @default.
• W2741796350 isRetracted "false" @default.
• W2741796350 magId "2741796350" @default.
• W2741796350 workType "article" @default.